Attached files
| file | filename |
|---|---|
| EX-10.1 - FORM OF AMENDMENT TO NOTE CONVERSION AGREEMENT - GT Biopharma, Inc. | exhibittenone.htm |
| EX-99 - LIST OF SOME CONVERTING WARRANTHOLDERS - GT Biopharma, Inc. | exhibitninetynine.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 Or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 19, 2016
OXIS INTERNATIONAL, INC.
(Exact name of Registrant as specified in its charter)
____________________
|
Delaware
(State or other Jurisdiction of Incorporation or organization)
|
000-08092
(Commission File Number)
|
94-1620407
(IRS Employer I.D. No.)
|
___________________________
100 South Ashley Drive
Suite 600
Tampa, FL 33602
Phone: (800) 304-9888
(Address, including zip code, and telephone and facsimile numbers, including area code, of
registrant’s executive offices)
___________________________
N/A
|
(Former name, former address and former fiscal year, if changed since last report)
|
- 1 -
|
ITEM 1.01.
|
ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
|
On February 19, 2016, Oxis International, Inc. (the “Company”) entered into an amendment (the “Amendment”) to that certain note conversion agreement dated January 8, 2016 (the “Conversion Agreement”). As previously disclosed, under the Conversion Agreement, the investor parties thereto agreed to convert certain outstanding promissory notes into shares of the Company’s common stock upon the closing of a financing, as described in the Conversion Agreement, occurring on or before February 15, 2016. The Amendment extends such deadline from February 15, 2016 to March 15, 2016.
The foregoing summary of the Amendment does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Amendment, which is attached hereto as Exhibits 10.1, and is incorporated herein by reference.
ITEM 8.01 OTHER EVENTS
On January 22, 2016, the Company filed a current report on Form 8-K disclosing the issuance of shares of common stock in exchange for the cancellation of warrants on a cashless basis. Some of the persons who received common shares in exchange for the cancellation of warrants together with the number of common shares received by them are set forth on Exhibit 99.
|
ITEM 9.01.
|
FINANCIAL STATEMENTS AND EXHIBITS
|
|
Exhibit No.
|
|
Description
|
|
10.1
99
|
|
Form of Amendment to Note Conversion Agreement
Schedule of Certain Shareholders
|
SIGNATURE PAGE
Pursuant to the requirement of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Oxis International, Inc.
Dated: February 19, 2016 By: /s/ Anthony J. Cataldo
Anthony J. Cataldo,
Chief Executive Officer
EXHIBIT INDEX
|
Exhibit No.
|
|
Description
|
|
10.1
99
|
|
Form of Amendment to Note Conversion Agreement
Schedule of Certain Shareholders
|
- 2 -